Mr. William V. Williams reports

BRIACELL THERAPEUTICS ANNOUNCES PRICING OF $5.5 MILLION PUBLIC OFFERING

Briacell Therapeutics Corp. has priced an underwritten public offering of 7.4 million common shares and warrants to purchase 7.4 million common shares at a combined public offering price of 75 cents per share and associated warrant. The warrants will have an exercise price of 93.75 cents per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the company. Total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses, are expected to be approximately $5.55-million. The offering is expected to close on Dec. 13, 2024, subject to satisfaction of customary closing conditions. The company is relying upon the exemption set forth in Section 602.1 of the TSX company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Stock Market.

The company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes and the advancement of business objectives.

ThinkEquity is acting as the sole bookrunning manager for the offering.

The securities described herein are being offered and sold by the company pursuant to a shelf registration statement on Form S-3 (file No. 333-276650), including a base prospectus, filed with the United States Securities and Exchange Commission (SEC) on Jan. 22, 2024, and declared effective on Jan. 31, 2024. The offering is being made only by means of a written prospectus. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and can be accessed, without charge, on the SEC's website. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from the offices of ThinkEquity, 17 State St., 41st floor, New York, N.Y., 10004.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.